June 10, 2009 (FinancialWire) — Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that nine presentations will be given at the 56th annual meeting of the Society of Nuclear Medicine, scheduled for June 13 - 17, 2009, in Toronto, Canada.

The schedule and meeting places for the oral presentations and scientific poster sessions, together with the publication numbers are listed below:

 * “Durable responses with Y-epratuzumab fractionated radioimmunotherapy in NHL” (Publication No. 45, Sunday, June 14, 1: 33 p.m. - 1: 45 p.m., Scientific Paper Session, Session Info: Radiopharmaceutical Therapy I, Room 707)

 * “Pretargeted radioimmunotherapy (PT-RAIT) in progressive medullary thyroid cancer ” (Publication No. 105, Sunday, June 14, 4: 15 p.m. - 5: 45 p.m., Scientific Paper Session, Session Info:  Nuclear Oncology Council Young Investigator Award Symposium, Room 707)

 * “A novel method of radiolabeling peptides with aluminum-fluoride-18 (AlF-18) using various NOTA derivatives” (Publication No. 202, Monday, June 15, 12: 42 p.m. - 12: 54 p.m., Scientific Paper Session

 , Session Info: General Applications II, Room 713B)

 * “Pretargeted immunoPET for imaging colorectal cancer in a mouse model” (Publication No. 381, Tuesday, June 16, 9: 45 a.m. - 9: 57 a.m., Scientific Paper Session, Session Info: Antibodies and Larger Molecules, Room 707)

 * “(18)F labeling of a peptide for PET imaging of receptor-expressing tumors” (Publication No. 1567, Tuesday, June 16, 4: 30 p.m. - 5: 15 p.m., Scientific Poster Session, Poster Section: Basic Science Posters, Exhibit Hall E/F)

 * “Pretargeted radioimmunotherapy effectively inhibits growth of subcutaneous colon carcinoma xenografts in nude mice” (Publication No. 1570, Tuesday, June 16, 4: 30 p.m. - 5: 15 p.m., Scientific Poster Session, Poster Section: Basic Science Posters, Exhibit Hall E/F)

 * “(90)Y-hPAM4 radioimmunotherapy plus radiosensitizing gemcitabine in advanced pancreatic cancer ” (Publication No. 1614, Tuesday, June 16, 4: 30 p.m. - 5: 15 p.m., Scientific Poster Session, Poster Section: Therapy Metrics and Intervention Posters, Exhibit Hall E/F)

 * “Fractionated pretargeted radioimmunotherapy (PT-RAIT) of pancreatic cancer xenografts” (Publication No. 1639, Tuesday, June 16, 4: 30 p.m. - 5: 15 p.m., Scientific Poster Session, Poster Section: Therapy Metrics and Intervention Posters, Exhibit Hall E/F)

 * “Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin’s lymphoma shows improved efficacy” (Publication No. 574, Wednesday, June 17, 8: 12 a.m. - 8: 24 a.m., Scientific Paper Session, Session Info:  Translation Nuclear Medicine, Room 707)

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.